N-Lactase

N-Lactase may be available in the countries listed below.

Ingredient matches for N-Lactase

Tilactase

Tilactase is reported as an ingredient of N-Lactase in the following countries:

• Japan

International Drug Name Search

Talacen

In the US, Talacen (acetaminophen/pentazocine systemic) is a member of the drug class narcotic analgesic combinations and is used to treat Pain.

US matches:

• Talacen

Ingredient matches for Talacen

Paracetamol

Paracetamol is reported as an ingredient of Talacen in the following countries:

• United States

Pentazocine

Pentazocine hydrochloride (a derivative of Pentazocine) is reported as an ingredient of Talacen in the following countries:

• United States

International Drug Name Search

Prefest

In the US, Prefest (estradiol/norgestimate systemic) is a member of the drug class sex hormone combinations and is used to treat Atrophic Urethritis, Atrophic Vaginitis, Postmenopausal Symptoms and Prevention of Osteoporosis.

US matches:

• Prefest

Ingredient matches for Prefest

Estradiol

Estradiol is reported as an ingredient of Prefest in the following countries:

• Brazil

Ethinylestradiol

Ethinylestradiol is reported as an ingredient of Prefest in the following countries:

• United States

Norgestimate

Norgestimate is reported as an ingredient of Prefest in the following countries:

• United States

International Drug Name Search

Fosinopril HCT Winthrop

Fosinopril HCT Winthrop may be available in the countries listed below.

Ingredient matches for Fosinopril HCT Winthrop

Fosinopril

Fosinopril sodium salt (a derivative of Fosinopril) is reported as an ingredient of Fosinopril HCT Winthrop in the following countries:

• Australia

Hydrochlorothiazide

Hydrochlorothiazide is reported as an ingredient of Fosinopril HCT Winthrop in the following countries:

• Australia

International Drug Name Search

Robinul

glycopyrrolate

Dosage Form: tablet
Robinul and Robinul Forte

Robinul® and Robinul® Forte

(Glycopyrrolate Tablets, USP)

Rx Only

Code: 883C00          Rev. 04/10

Robinul Description

Robinul® and Robinul® Forte tablets contain the synthetic anticholinergic, glycopyrrolate.  Glycopyrrolate is a quaternary ammonium compound with the following chemical name: 3-[(cyclopentylhydroxyacetyl)oxy]-1,1-dimethylpyrrolidinium bromide.

 

Robinul tablets are scored, compressed white tablets engraved HPC 200.  Each tablet contains:

Glycopyrrolate, USP………..1 mg

 

Robinul Forte tablets are scored, compressed white tablets engraved HORIZON 205.  Each tablet contains:

Glycopyrrolate, USP……….2 mg

 

Inactive Ingredients: Dibasic Calcium Phosphate, Lactose, Magnesium Stearate, Povidone, Sodium Starch Glycolate

ACTIONS

Glycopyrrolate, like other anticholinergic (antimuscarinic) agents, inhibits the action of acetylcholine on structures innervated by postganglionic cholinergic nerves and on smooth muscles that respond to acetylcholine by lack cholinergic innervation.  These peripheral cholinergic receptors are present in the autonomic effector cells of smooth muscle, cardiac muscle, the sino-atrial node, the atrioventricular node, exocrine glands, and, to a limited degree, in the autonomic ganglia.  Thus, it diminishes the volume and free acidity of gastric secretions and controls excessive pharyngeal, tracheal, and bronchial secretions.

 

Glycopyrrolate antagonizes muscarinic symptoms (e.g., bronchorrhea, bronchospasm, bradycardia, and intestinal hypermotility) induced by cholinergic drugs such as the anticholinesterases.

 

The highly polar quaternary ammonium group of glycopyrrolate limits its passage across lipid membranes, such as the blood-brain barrier, in contrast to atropine sulfate and scopolamine hydrobromide, which are non-polar tertiary amines which penetrate lipid barriers easily.

INDICATIONS

For use as adjunctive therapy in the treatment of peptic ulcer.

Contraindications

Glaucoma; obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); paralytic ileus; intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis.  Robinul (glycopyrrolate) tablets are contraindicated in those patients with a hypersensitivity to glycopyrrolate.

Warnings

In the presence of a high environmental temperature, heal prostration (fever and heat stroke due to decreased sweating) can occur with the use of Robinul.

 

Diarrhea may be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy.  In this instance treatment with this drug would be inappropriate and possibly harmful.

 

Robinul (glycopyrrolate) may produce drowsiness or blurred vision.  In this event, the patient should be warned not to engage in activities requiring mental alertness such as operating a motor vehicle or other machinery, or performing hazardous work while taking this drug. 

 

Theoretically, with overdosage, a curare-like action may occur, i.e., neuro-muscular blockade leading to muscular weakness and possible paralysis.

Pregnancy

The safety of this drug during pregnancy has not been established.  The use of any drug during pregnancy requires that the potential benefits of the drug be weighed against possible hazards to mother and child.  Reproduction studies in rats revealed no teratogenic effects from glycopyrrolate; however, the potent anticholinergic action of this agent resulted in diminished rates of conception and of survival at weaning, in a dose-related manner.  Other studies in dogs suggest that this may be due to diminished seminal secretion which is evident at high doses of glycopyrrolate.  Information on possible adverse effects in the pregnant female is limited to uncontrolled data derived from marketing experience.  Such experience has revealed no reports of teratogenic or other fetus-damaging potential.  No controlled studies to establish the safety of the drug in pregnancy have been performed.

Nursing Mothers

It is not know whether this drug is excreted in human milk.  As a general rule, nursing should not be undertaken while a patient is on a drug since many drugs are excreted in human milk.

Pediatric Use

Since there is no adequate experience in pediatric patients who have received this drug, safety and efficacy in pediatric patients have not been established.

Precautions

Use Robinul with caution in the elderly and in all patients with:

 

• Autonomic neuropathy.


• Hepatic or renal disease.


• Ulcerative colitis - large doses may suppress intestinal motility to the point of producing a paralytic ileus and for this reason may precipitate or aggravate the "toxic megacolon," a serious complication of the disease.


• Hyperthyroidism, coronary heart disease, congestive heart failure, cardiac tachyarrhythmias, tachycardia, hypertension and prostatic hypertrophy.


• Hiatal hernia associated with reflux esophagitis, since anticholinergic drugs may aggravate this condition.

 

 

Adverse Reactions

Anticholinergics produce certain effects, most of which are extensions of their fundamental pharmacological actions.  Adverse reactions to anticholinergics in general may include xerostomia; decreased sweating; urinary hesitancy and retention; blurred vision; tachycardia; palpitations; dilation of the pupil; cycloplegia; increased ocular tension; loss of taste; headaches; nervousness; mental confusion; drowsiness; weakness; dizziness; insomnia; nausea; vomiting; constipation; bloated feeling; impotence; suppression of lactation; severe allergic reaction or drug idiosyncrasies including anaphylaxis, urticaria and other dermal manifestations.

 

Robinul (glycopyrrolate) is chemically a quaternary ammonium compound; hence, its passage across lipid membranes, such as the blood-brain barrier, is limited in contrast to atropine sulfate and scopolamine hydrobromide.  For this reason the occurrence of CNS related side effects is lower, in comparison to their incidence following administration of anticholinergics which are chemically tertiary amines that can cross this barrier readily.

Overdosage

The symptoms of overdosage of glycopyrrolate are peripheral in nature rather than central.

 

1. To guard against further absorption of the drug - use gastric lavage, cathartics, and/or enemas.


2. To combat peripheral anticholinergic effects (residual mydriasis, dry mouth, etc.) - utilize a quaternary ammonium anticholinesterase, such as neostigmine methylsulfate.


3. To combat hypotension - use pressor amines (norepinephrine, metaraminol) i.v.; and supportive care.


4. To combat respiratory depression - administer oxygen; utilize a respiratory stimulant such as Dopram® i.v.; artificial respiration.

Robinul Dosage and Administration

The dosage of Robinul® or Robinul® Forte should be adjusted to the needs of the individual patient to assure symptomatic control with a minimum of adverse reactions. The presently recommended maximum daily dosage of glycopyrrolate is 8 mg.

 

Robinul (glycopyrrolate, 1 mg) tablets.  The recommended initial dosage of Robinul for adults is one tablet three times daily (in the morning, early afternoon, and at bedtime).  Some patients may require two tablets at bedtime to assure overnight control of symptoms.  For maintenance, a dosage of one tablet twice a day is frequently adequate.

 

Robinul Forte (glycopyrrolate, 2 mg) tablets.  The recommended dosage of Robinul Forte for adults is one tablet two or three times daily at equally spaced intervals.

 

Robinul tablets are not recommended for use in pediatric patients under the age of 12 years.

Drug Interactions

There are no known drug interactions.

How is Robinul Supplied

Robinul® (glycopyrrolate, 1 mg) tablets in bottles of 100 (NDC 59630-200-10).

 

Robinul® Forte (glycopyrrolate, 2 mg) tablets in bottles of 100 (NDC 59630-205-10).

 

Store at controlled room temperature, 20˚C to 25˚C (68˚F to 77˚F); excursions permitted to 15˚C-30˚C (59˚F-86˚F) [See USP Controlled Room Temperature].  Keep out of reach of children.

 

Dispense in tight container.

 

Rx only

 

ROB-PI-2

Rev. 04 / 10                 Code 883C00                Printed in USA

 

Manufactured by:

MIKART, INC.

Atlanta, GA 30318

 

Manufactured for:

SHIONOGI PHARMA, INC.

Atlanta, GA 30328

PRINCIPAL DISPLAY PANEL - 1 mg Bottle Label

NDC 59630-200-10

100 Tablets

Robinul®

(glycopyrrolate tablets, USP)

1 mg

WHITE DYE-FREE

Manufactured for :

SHIONOGI PHARMA, INC.

Atlanta, GA 30328    U.S. Patent No. 7,091,236

PRINCIPAL DISPLAY PANEL - 2 mg Bottle Label

NDC 59630-205-10

100 Tablets

Robinul®

(glycopyrrolate

tablets, USP)

2 mg

WHITE DYE-FREE

Manufactured for :

SHIONOGI PHARMA, INC.

Atlanta, GA 30328

U.S. Patent No. 7,091,236

Robinul  glycopyrrolate  tablet

Product Information Product Type HUMAN PRESCRIPTION DRUG NDC Product Code (Source) 59630-200 Route of Administration ORAL DEA Schedule

Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength GLYCOPYRROLATE (GLYCOPYRROLATE) GLYCOPYRROLATE 1 mg

Inactive Ingredients Ingredient Name Strength ANHYDROUS DIBASIC CALCIUM PHOSPHATE   LACTOSE   MAGNESIUM STEARATE   POVIDONE

Product Characteristics Color WHITE (white) Score 2 pieces Shape ROUND (ROUND) Size 8mm Flavor Imprint Code HPC;200 Contains

Packaging # NDC Package Description Multilevel Packaging 1 59630-200-10 100 TABLET In 1 BOTTLE None

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA012827	03/28/1961

Robinul FORTE  glycopyrrolate  tablet

Product Information Product Type HUMAN PRESCRIPTION DRUG NDC Product Code (Source) 59630-205 Route of Administration ORAL DEA Schedule

Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength GLYCOPYRROLATE (GLYCOPYRROLATE) GLYCOPYRROLATE 2 mg

Inactive Ingredients Ingredient Name Strength ANHYDROUS DIBASIC CALCIUM PHOSPHATE   LACTOSE   MAGNESIUM STEARATE   POVIDONE

Product Characteristics Color WHITE (white) Score 2 pieces Shape ROUND (ROUND) Size 10mm Flavor Imprint Code HORIZON;205 Contains

Packaging # NDC Package Description Multilevel Packaging 1 59630-205-10 100 TABLET In 1 BOTTLE None

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA012827	03/28/1961

Labeler - Shionogi Pharma, Inc. (802728477)

Revised: 12/2010Shionogi Pharma, Inc.

More Robinul resources

• Robinul Side Effects (in more detail)
• Robinul Dosage
• Robinul Use in Pregnancy & Breastfeeding
• Drug Images
• Robinul Drug Interactions
• Robinul Support Group
• 0 Reviews for Robinul - Add your own review/rating

• Robinul Monograph (AHFS DI)


• Robinul Advanced Consumer (Micromedex) - Includes Dosage Information


• Robinul MedFacts Consumer Leaflet (Wolters Kluwer)


• Glycopyrrolate Professional Patient Advice (Wolters Kluwer)


• Cuvposa Solution MedFacts Consumer Leaflet (Wolters Kluwer)


• Cuvposa Consumer Overview


• Robinul Forte MedFacts Consumer Leaflet (Wolters Kluwer)

Compare Robinul with other medications

• Anesthesia
• Peptic Ulcer

Travasept

Travasept may be available in the countries listed below.

Ingredient matches for Travasept

Cetrimide

Cetrimide is reported as an ingredient of Travasept in the following countries:

• United Kingdom

Chlorhexidine

Chlorhexidine diacetate (a derivative of Chlorhexidine) is reported as an ingredient of Travasept in the following countries:

• United Kingdom

International Drug Name Search

Klacar

Klacar may be available in the countries listed below.

Ingredient matches for Klacar

Clarithromycin

Clarithromycin is reported as an ingredient of Klacar in the following countries:

• Bulgaria

International Drug Name Search

Trankitec

Trankitec may be available in the countries listed below.

Ingredient matches for Trankitec

Valproic Acid

Valproic Acid magnesium (a derivative of Valproic Acid) is reported as an ingredient of Trankitec in the following countries:

• Mexico

International Drug Name Search

Zolazepam Hydrochloride

Zolazepam Hydrochloride may be available in the countries listed below.

Ingredient matches for Zolazepam Hydrochloride

Zolazepam

Zolazepam Hydrochloride (BAN, USAN) is also known as Zolazepam (Rec.INN)

International Drug Name Search

Glossary

BAN	British Approved Name
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Noxidem

Noxidem may be available in the countries listed below.

Ingredient matches for Noxidem

Zolpidem

Zolpidem tartrate (a derivative of Zolpidem) is reported as an ingredient of Noxidem in the following countries:

• South Africa

International Drug Name Search